文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

贝伐珠单抗或激光光凝治疗早产儿视网膜病变婴儿的中央凹发育

Foveal Development in Infants Treated with Bevacizumab or Laser Photocoagulation for Retinopathy of Prematurity.
PubMed 文献 · Ophthalmology · 2017-11-02

这项观察性病例系列对131例接受早产儿视网膜病变筛查的早产儿进行纵向手持OCT成像,比较贝伐珠单抗眼、激光光凝眼与未治疗眼的中央凹发育。结果显示贝伐珠单抗治疗眼中央凹外层视网膜增厚更快,激光光凝眼内层视网膜挤出更早且椭圆体带出现延迟,需长期随访确定视觉意义。

要点

  • 贝伐珠单抗治疗眼中央凹外层视网膜增厚速度为7.2微米/周,未治疗眼为3.1微米/周(P=0.038)。
  • 激光光凝眼中央凹内层视网膜完全存在的概率较低(比值比0.04,P=0.001)。
  • 激光光凝眼中央凹椭圆体带存在的概率较低(比值比0.07,P=0.024)。

核心结论

  • 玻璃体腔注射贝伐珠单抗治疗早产儿视网膜病变与中央凹外层视网膜增厚更快相关,而激光光凝与中央凹内层视网膜更早挤出及椭圆体带发育延迟相关。
  • 需要长期随访以确定这些发现的视觉意义。

研究设计与样本

  • 观察性病例系列,纳入131例接受早产儿视网膜病变筛查的早产儿。
  • 对所有患者纵向进行手持OCT成像,测量中央凹中心及鼻侧、颞侧中央凹缘的内层和外层视网膜厚度。
  • 治疗眼与未治疗眼的比较针对年龄和其他混杂变量进行了校正。

主要发现

  • 未治疗眼中央凹中心外层视网膜厚度增加3.1微米/周,贝伐珠单抗治疗眼为7.2微米/周(P=0.038)。
  • 与未治疗眼相比,激光光凝治疗眼中央凹中心所有内层视网膜层存在的概率较低(比值比0.04,P=0.001)。
  • 与未治疗眼相比,激光光凝治疗眼中央凹中心椭圆体带存在的概率较低(比值比0.07,P=0.024)。
  • 囊样黄斑改变见于53%的患者和22%的成像 sessions。
  • 囊样黄斑改变的年龄校正发病率与贝伐珠单抗或激光光凝治疗无关。

局限性

  • 需要长期随访以确定这些发现的视觉意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize and quantify early foveal development in preterm infants and to compare this development between eyes treated with intravitreal bevacizumab or laser photocoagulation (LPC) and untreated eyes. DESIGN: Observational case series. PARTICIPANTS: One hundred thirty-one preterm infants undergoing retinopathy of prematurity (ROP) screenings. METHODS: Handheld OCT imaging was performed longitudinally on all patients. Thickness measurements of the inner and outer retinal layers were obtained at the foveal center and the nasal and temporal foveal rims. Comparisons between treated and untreated eyes were adjusted for age and other confounding variables. MAIN OUTCOME MEASURES: Weekly change in inner and outer retinal thickness and presence of inner retinal layers, ellipsoid zone (EZ), and cystoid macular changes (CMCs). RESULTS: Outer retinal thickness at the foveal center increased by 3.1 μm/week in untreated eyes and 7.2 μm/week in bevacizumab-treated eyes (P = 0.038). Eyes treated with LPC had a lower probability of having all inner retinal layers present at the foveal center (odds ratio, 0.04; P = 0.001) and a lower probability of having the EZ present at the foveal center (odds ratio, 0.07; P = 0.024) compared with untreated eyes. Cystoid macular changes were found in 53% of patients and 22% of imaging sessions. The age-adjusted incidence of CMCs was not correlated with bevacizumab or LPC treatment. CONCLUSIONS: Intravitreal bevacizumab therapy for ROP is associated with more rapid outer retinal thickening at the foveal center, whereas LPC is associated with earlier extrusion of the inner retinal layers and delayed development of the EZ at the foveal center. Long-term follow-up is needed to determine the visual significance of these findings.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Vogel RN, Strampe M, Fagbemi OE, et al. Foveal Development in Infants Treated with Bevacizumab or Laser Photocoagulation for Retinopathy of Prematurity. Ophthalmology. 2017. PMID: 29103792. doi:10.1016/j.ophtha.2017.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。